ATE510850T1 - Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten - Google Patents

Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten

Info

Publication number
ATE510850T1
ATE510850T1 AT01971181T AT01971181T ATE510850T1 AT E510850 T1 ATE510850 T1 AT E510850T1 AT 01971181 T AT01971181 T AT 01971181T AT 01971181 T AT01971181 T AT 01971181T AT E510850 T1 ATE510850 T1 AT E510850T1
Authority
AT
Austria
Prior art keywords
murine
tlr8
tlr7
tlr9
well
Prior art date
Application number
AT01971181T
Other languages
English (en)
Inventor
Stefan Bauer
Grayson Lipford
Hermann Wagner
Original Assignee
Coley Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Gmbh filed Critical Coley Pharm Gmbh
Application granted granted Critical
Publication of ATE510850T1 publication Critical patent/ATE510850T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01971181T 2000-09-15 2001-09-17 Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten ATE510850T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23303500P 2000-09-15 2000-09-15
US26365701P 2001-01-23 2001-01-23
US29172601P 2001-05-17 2001-05-17
US30021001P 2001-06-22 2001-06-22
PCT/US2001/029229 WO2002022809A2 (en) 2000-09-15 2001-09-17 PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST

Publications (1)

Publication Number Publication Date
ATE510850T1 true ATE510850T1 (de) 2011-06-15

Family

ID=27499675

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01971181T ATE510850T1 (de) 2000-09-15 2001-09-17 Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten

Country Status (8)

Country Link
US (2) US6943240B2 (de)
EP (1) EP1366077B1 (de)
JP (1) JP2005500806A (de)
AT (1) ATE510850T1 (de)
AU (1) AU2001291096A1 (de)
CA (1) CA2419894A1 (de)
DK (1) DK1366077T3 (de)
WO (1) WO2002022809A2 (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20020086368A1 (en) * 1997-10-17 2002-07-04 Genentech Inc Human toll homologues
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002514397A (ja) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー CpGオリゴヌクレオチドを用いる造血調節の方法
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1296714B1 (de) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
JP2002034565A (ja) 2000-07-19 2002-02-05 Japan Science & Technology Corp 細菌dnaを特異的に認識する受容体タンパク質
JP2005500806A (ja) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー CpGに基づく免疫アゴニスト/免疫アンタゴニストの高スループットスクリーニングのためのプロセス
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
ATE411054T1 (de) 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
CN1633598A (zh) * 2001-10-05 2005-06-29 科勒制药股份公司 Toll样受体3信号传导的激动剂和拮抗剂
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
DE60236686D1 (de) * 2001-11-22 2010-07-22 Dainippon Sumitomo Pharma Co Nichtmenschliches tiermodell, das nicht auf eine immunopotenzierende synthetische verbindung anspricht
EP1465657A4 (de) * 2001-12-18 2006-02-01 Health Research Inc Verfahren zur verstärkung der immunogenität durch kovalente verknüpfung von antigenen mit proteinen auf der oberfläche dendritischer zellen
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
EP3006043B1 (de) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatorische g,u-haltige oligoribonucleotide
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CN1753687A (zh) * 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
WO2004070344A2 (en) * 2003-02-04 2004-08-19 Bayer Healthcare Ag Method of screening for agents which modulate the activity of tlr9
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
EP1599726A4 (de) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selektive modulation von tlr-vermittelter biologischer aktivität
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1631687A2 (de) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden
MXPA05013922A (es) * 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1678303A2 (de) 2003-10-30 2006-07-12 Coley Pharmaceutical GmbH C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (de) 2003-11-14 2008-10-22 3M Innovative Properties Co Oximsubstituierte imidazoringverbindungen
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
WO2005072097A2 (en) 2003-12-16 2005-08-11 University Of Massachusetts Toll-like receptor 9 modulators
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (de) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
US20050244410A1 (en) * 2004-04-29 2005-11-03 Ashlyn Bassiri Toll-like receptor 9 effector agents and uses thereof
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
GB0424497D0 (en) * 2004-11-05 2004-12-08 Univ Sheffield Anti-inflammatory agent
JP5149013B2 (ja) 2004-11-29 2013-02-20 セクエノム,インコーポレイティド メチル化dnaを検出する手段、及び方法
US9249464B2 (en) 2004-11-29 2016-02-02 Sequenom, Inc. Kits and methods for detecting methylated DNA
US20210371901A1 (en) * 2004-11-29 2021-12-02 Sequenom, Inc. Kits and Methods for Detecting Methylated DNA
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
EP1831221B1 (de) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituierte, chirale, fusionierte 1,2 imidazo-4,5-c-ringverbindungen
JP4836145B2 (ja) * 2005-01-28 2011-12-14 クウォン,ヒュン−ジョ マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および/または正常免疫細胞保護用オリゴヌクレオチド
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
DE102005005642A1 (de) * 2005-02-06 2006-08-10 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Nukleinsäuren, die zur Ausbildung von stem-loop-Sekundärstrukturen geeignete Sequenzen umfassen
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
US7498409B2 (en) * 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
US7700728B2 (en) * 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
JP2008148556A (ja) * 2005-03-31 2008-07-03 Univ Of Tokyo インターフェロン−α及び/又はβ(IFN−α/β)の発現誘導を促進する補助剤のスクリーニングする方法
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006241149A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
ATE439135T1 (de) 2005-07-01 2009-08-15 Index Pharmaceuticals Ab Modulierung der reaktion auf steroide
AU2006266503B2 (en) 2005-07-01 2011-12-08 Index Pharmaceuticals Ab Immunostimulatory method
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
WO2007038720A2 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
AU2006315632A1 (en) * 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
JP4538522B2 (ja) 2005-11-25 2010-09-08 コーリー ファーマシューティカル ゲーエムベーハー 免疫刺激性オリゴリボヌクレオチド
CA2649387A1 (en) * 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US20080171716A1 (en) * 2006-08-16 2008-07-17 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
WO2009013159A2 (en) * 2007-07-23 2009-01-29 Dsm Ip Assets B.V. Acetyl-coa producing enzymes in yeast
US20100040576A1 (en) * 2007-12-18 2010-02-18 The Texas A&M University System Modified Oligonucleotides For The Treatment Of Hepatitis C Infection
WO2010014572A2 (en) * 2008-07-28 2010-02-04 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 9 expression by antisense oligonucleotides
JP5701766B2 (ja) * 2008-11-11 2015-04-15 メルク パテント ゲーエムベーハー 有機エレクトロルミネセント素子
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
EP2451974A2 (de) * 2009-07-08 2012-05-16 Idera Pharmaceuticals, Inc. Oligonukleotidbasierte verbindungen als toll-like-rezeptorhemmer
EP2493921B1 (de) 2009-10-30 2018-09-26 Albumedix Ltd Albuminvarianten
EP2556087A1 (de) * 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albuminderivate und varianten
JP5686814B2 (ja) * 2010-09-17 2015-03-18 独立行政法人科学技術振興機構 Hmgbタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
WO2013119193A2 (en) * 2010-10-21 2013-08-15 Tufts University Extracellular mitochondria-based screening and treatment
US9063123B2 (en) 2011-03-29 2015-06-23 Dynavax Technologies Corporation Transgenic mice expressing human toll-like receptor 8
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
EP2780364A2 (de) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteine mit verbesserter halbwertzeit und anderen eigenschaften
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US9556439B2 (en) * 2012-02-09 2017-01-31 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (TLR) 13
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
EP2943512A4 (de) * 2013-01-11 2016-06-01 California Inst Biomedical Res Bovine fusionsantikörper
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
JPWO2015108048A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108047A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
AU2018293925B2 (en) * 2017-06-30 2024-06-13 Adelaide university A method of treatment
WO2020041590A1 (en) * 2018-08-23 2020-02-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tlr9 ligand trap
US11393560B2 (en) 2018-11-13 2022-07-19 Recursion Pharmaceuticals, Inc. Systems and methods for high throughput compound library creation
WO2021146383A1 (en) * 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
JP7757800B2 (ja) * 2022-01-14 2025-10-22 株式会社島津製作所 電気泳動システム、電気泳動装置、電気泳動解析方法、および、電気泳動解析プログラム
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位
US12416020B2 (en) * 2024-02-20 2025-09-16 Wyvern Pharmaceuticals Inc. Plasmid encoding a TLR3 and Fc fusion protein

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567604A (en) 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (de) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatorische Oligonukleotide
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
EP0810882A4 (de) 1995-02-09 1999-05-19 Icn Pharmaceuticals Verfahren und zusammensetzung für die regulation der cd28-expression
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0968226A4 (de) 1996-12-27 2001-02-14 Icn Pharmaceuticals Oligoaptamere mit g-angereicherten regionen und methoden zur modulation einer immunantwort
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2331622T3 (es) 1997-05-07 2010-01-11 Schering Corporation Proteinas receptoras humanas similares a toll, reactivos y metodos relacionados.
EP1003531B1 (de) 1997-05-20 2007-08-22 Ottawa Health Research Institute Verfahren zur Herstellung von Nukleinsäurekonstrukten
WO1999001154A1 (en) 1997-07-03 1999-01-14 University Of Iowa Research Foundation Method for inhibiting immunostimulatory dna associated responses
PT1887014E (pt) 1997-10-17 2010-07-05 Genentech Inc Homëlogos de toll humana
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2002514397A (ja) 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー CpGオリゴヌクレオチドを用いる造血調節の方法
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション CpGオリゴヌクレオチドの立体異性体および関連する方法
WO2000014217A2 (en) 1998-09-03 2000-03-16 Coley Pharmaceutical Gmbh G-motif oligonucleotides and uses thereof
ATE442774T1 (de) 1999-01-14 2009-10-15 Japan Science & Tech Agency Myod-knockout maus als bakterienzellwandbestandteil-unansprechender tiermodell
EP1177439B1 (de) 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening nach modulatoren der funktion von immunstimulatorischer dna
EP1377554A1 (de) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonismus der immunostimulatorischen cpg-oligonukleotiden durch 4-aminochinolinen und sonstigen schwachen basen
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU783118B2 (en) 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
WO2001036641A2 (en) 1999-11-02 2001-05-25 Chiron Corporation DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
GB0001704D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US6339630B1 (en) * 2000-05-18 2002-01-15 The United States Of America As Represented By The United States Department Of Energy Sealed drive screw operator
EP1296714B1 (de) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
JP2005500806A (ja) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー CpGに基づく免疫アゴニスト/免疫アンタゴニストの高スループットスクリーニングのためのプロセス
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
WO2002053141A2 (en) * 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002360243A1 (en) 2001-07-26 2003-05-06 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
ATE411054T1 (de) * 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
US20030067902A1 (en) * 2001-09-21 2003-04-10 Skeba Kirk W. Method for providing multiple certified radio modules with a baseband
CN1633598A (zh) * 2001-10-05 2005-06-29 科勒制药股份公司 Toll样受体3信号传导的激动剂和拮抗剂
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
EP1455700A4 (de) 2001-11-16 2007-02-14 3M Innovative Properties Co Verfahren und zusammensetzungen im zusammenhang mit irm-verbindungen und toll-rezeptor-pfaden
EP3006043B1 (de) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatorische g,u-haltige oligoribonucleotide
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en) 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
AU2003278845A1 (en) 2002-09-19 2004-04-08 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
CN1753687A (zh) * 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
AU2004226605A1 (en) 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1631687A2 (de) 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden
MXPA05013922A (es) * 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
EP1678303A2 (de) * 2003-10-30 2006-07-12 Coley Pharmaceutical GmbH C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
JP2007526253A (ja) 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
JP2007531746A (ja) * 2004-04-02 2007-11-08 コーリー ファーマシューティカル グループ,インコーポレイテッド Il−10応答を誘導するための免疫活性化核酸
EP1776105A2 (de) * 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Verfahren und zusammensetzungen zur induzierung eigener immunantworten

Also Published As

Publication number Publication date
US20030104523A1 (en) 2003-06-05
AU2001291096A1 (en) 2002-03-26
WO2002022809A3 (en) 2003-10-02
WO2002022809A2 (en) 2002-03-21
EP1366077B1 (de) 2011-05-25
JP2005500806A (ja) 2005-01-13
WO2002022809A9 (en) 2003-03-20
CA2419894A1 (en) 2002-03-21
US7820379B2 (en) 2010-10-26
DK1366077T3 (da) 2011-09-12
US6943240B2 (en) 2005-09-13
EP1366077A2 (de) 2003-12-03
US20050181422A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
ATE510850T1 (de) Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE470712T1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
MY143322A (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
ATE554784T1 (de) Hochaffiner ligand für p75 neurotrophin-rezeptor
WO2003086280A3 (en) Immunostimulatory g,u-containing oligoribonucleotides
EP0876387A4 (de) Verfahren zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
DE60028732D1 (de) Verfahren zur erhaltung der dns-integrität
DE69834828D1 (de) Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
ATE257128T1 (de) Schwefelfreies lignin und dessen derivate zur herabsetzung der bildung von schleim und ablagerungen in industriellen anlagen
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
DE602004031642D1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
EP1246833A4 (de) Verbessertes verfahren zur synthese von sulfanisierten oligonucleotiden
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE50012831D1 (de) Verfahren zur verbindung von molekularen substanzen
DE60319369D1 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
DE602005026855D1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE315787T1 (de) Methoden zur identifizierung von modulatoren wechselwirkender proteine
ATE274351T1 (de) Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
DE60323120D1 (de) Verfahren zur modulierung von cytokininabhängigen vorgängen in einer pflanze mittels b3-domäne-proteinen
DE69731112D1 (de) Verfahren zur synthese von phosphorothioat-oligonukelotiden
ATE346957T1 (de) Verfahren zum nachweis von chloralhydrat in dichloressigsäure
DE50008085D1 (de) Verfahren zur Auswertung von Schäumvorgängen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties